Affordable Access

deepdyve-link
Publisher Website

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Authors
  • Carvajal-Hausdorf, Daniel E1, 2
  • Mani, Nikita3, 4
  • Velcheti, Vamsidhar5
  • Schalper, Kurt A3, 6, 4
  • Rimm, David L3
  • 1 Department of Pathology, Yale School of Medicine, New Haven, CT, USA. [email protected]
  • 2 Anatomía Patológica, Clínica Alemana- Facultad de Medicina Universidad del Desarrollo, Vitacura, Santiago, Chile. [email protected] , (Chile)
  • 3 Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
  • 4 Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, CT, USA.
  • 5 Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • 6 Anatomía Patológica, Clínica Alemana- Facultad de Medicina Universidad del Desarrollo, Vitacura, Santiago, Chile. , (Chile)
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Oct 17, 2017
Volume
5
Issue
1
Pages
81–81
Identifiers
DOI: 10.1186/s40425-017-0285-7
PMID: 29037255
Source
Medline
Keywords
License
Unknown

Abstract

IDO1 protein is expressed in the majority of HR+ BC and is an independent negative prognostic marker. Additionally, IDO1 expression is negatively associated with tumor B-cell infiltration. Measurement of IDO1 has the potential to identify a population that might derive benefit from IDO1 blockade.

Report this publication

Statistics

Seen <100 times